February saw several changes on boards at biotechs, bringing a diverse wealth of experience to support these companies. Read ...
US pharma major Johnson & Johnson (NYSE: JNJ) has won US approval for Tremfya (guselkumab) in the treatment of adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback